Gene W. Lee, PhD

PTC was excited to learn, share and collaborate with other leading RNA experts at the recent 7th Annual RNA-Targeted Drug Discovery & Development Summit in Boston, MA, and the RNA at the Bench and Bedside IV conference in La Jolla, CA. Anu Bhattacharyya, Kerstin Effenberger, and Marla Weetall from our research team presented on ways PTC is leveraging its leading splicing platform to identify promising therapies for rare diseases with high unmet need. Learn more about our splicing platform here: https://bit.ly/4fi4w6L

135

1 Comment

Excited to announce the 2025 Gordon Research Conference (GRC) on Protein Engineering, this second GRC on Protein Engineering will be held at Bryant University in Smithfield, RI from July 27th to August 1st 2025 https://lnkd.in/g-763SeF. please come join us if you would be interested in this exciting field. Different fields have experienced a transformative expansion in research distinction and capabilities. There now exists a strategic opportunity for protein engineering to take the lead and spearhead the integration of this joint effort, reflected by The Nobel Prize in Chemistry 2024. We believe that this GRC conference will create a gateway for the next generation of engineers and researchers, and will be a vehicle toward future development in the midst of an amazing convergence of multiple cutting-edge areas in protein engineering and its applications. Confirmed speakers include the Nobel Laureate Prof. Frances Arnold and distinctive scientists showing below: 1.            Fundamental Principles of Protein Engineering Possu Huang (Stanford University)/Frances Arnold (CalTech, Nobel Laureate)/Huimin Zhao (University of Illinois at Urbana-Champaign) 2.    Biosensors and Imaging Jennifer Prescher (UC Irvine)/Jin zhang (UC San Diego)/Robert Campbell (Tokyo University)/Nathan Shaner (UC San Diego) 3.    Rational Design of New-to Nature Proteins Jiri Damborsky (FNUSA-ICRC & Masaryk University, Czech Republic)/Joelle Pelletier (University of Montreal)/Sílvia Osuna (University of Girona & ICREA, Spain)/Koga Nobuyasu (Osaka Univ, Japan) 4.    AI for Protein engineering Zhongyue John Yang (Vanderbilt University)/ Jennifer Listgarten (UC Berkeley)/Doug Barrick (Johns Hopkins University) 5.    Biocatalysis and Industrial applications Carlos Martinez (Pfzer)/ Stephanie Galanie (Merck)/Zhi Li (National University of Singapore, Singapore)/Brent Dorr (Ginkgo Bioworks) 6.    Protein Engineering for Synthetic Biology Pimchai Chaiyen (Vidyasirimedhi Institute of Science and Technology (VISTEC), Thailand)/Weixin Tang (University of Chicago)/Jay Keasling (University of California, Berkeley) 7.    Directed Evolution for Enzyme Optimization Yang Yang (University of California Santa Barbara)/Leilei Zhu (Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, China)/Miguel Alcalde (Institute of Catalysis, CSIC, Spain)/Chang Liu (University of California, Irvine) 8.    Protein engineering for Immunotherapy and other diseases Anna Wu (Beckman Research Institute, City of Hope)/Xue Gao (University of Pennsylvania)/Bingfei Yu (University of Southern California)/Wilson Wong (Boston University) 9.    Repurposing Protein for Novel Chemistry and Applications Stefan Lutz (Codexis Inc)/Xiongyi Huang (Johns Hopkins University)/Xiaojing Gao (Stanford University)

46

3 Comments

Building new molecules is a challenge. A new AI tool is changing that by designing molecules piece by piece with a fragment-based approach.

1

Lake N. Paul, PhD. is in San Diego at the Biotechnology Innovation Organization #BIO2024 conference meeting with colleagues & future clients. Connect with him in person to learn about how, as a Collaborative Research Organization, we are best positioned to support your analytical program. #aav #genetherapy #rarediseases #biophysics #STEM #STEMPhilly #biochemistry #celltherapy #bioanalysisllc #PhillyBusiness #phillyscience

9

So Exciting! Johnson & Johnson 's Harsha Gunawardena is teaming up with Protein Metrics, LLC to do a webinar on Novilytic's #Proteometer fueled by #MASC. See https://bit.ly/4eCpPQh to learn how Harsha and his Team utilize this great software and AI to accelerate Biopharmaceutical Characterization and Quantification using MASC !!!

42

3 Comments

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

"The 12-month results from the PARADIGM Phase IIb study are encouraging, showing slowing disease progression and improved survival outcomes. This new analysis highlights PrimeC's ability to regulate the iron panel in people living with ALS, underscoring the drug's target engagement. These findings strongly support the proceeding to phase 3 testing of PrimeC in ALS." #NeuroSenseTherapeutics #ALSTreatment #ClinicalTrial #BiomarkerData #HealthcareInnovation #ProudMoment NeuroSense Therapeutics https://lnkd.in/dzVT6QWJ

54

Nice in depth (and nostalgic) analysis of the new Illumina SmolSeq (🐱) by Keith Robison. Some really insightful points, most importantly IMO that SmolSeq is artfully positioned to create some competitive turbulence for Element Biosciences: "But now, $50K gets a very highly performing machine and $100K one which will fit many startup aspirations.  AVITI is still a sweet instrument, but Illumina just made that conversation more complicated." Also, why so shy about a DX version - "But even more surprising is that Illumina didn't outline a clear roadmap for clinical versions of the MiSeq i100 [🐱] - the DX model of the MiSeq received FDA clearance. The simpler workflows and smaller footprint would seem to make MiSeq i100 [🐱] a natural to try to put into pathology labs. So why the hesitancy to outline a path to get these into lucrative clinical markets?"

78

16 Comments

Cell's fifth focus issue celebrating the journal's 50th anniversary expands upon its first anniversary focus issue on cell biology by directing our focus toward the future of the field. “Cell biology is so entwined with the origin of Cell and is growing in such exciting directions that we couldn’t stop with one 50th anniversary focus on the area,” says the Cell editorial team. “There are too many questions to ask.” This issue showcases areas where cell biology is forging ahead, including fresh looks at mitochondria and the concept of cell state alongside ideas about how to train the next generation of researchers. Learn about the people, technologies, and research driving the field of cell biology into the future. Explore the issue: https://lnkd.in/gtZU2iw9 #50YearsofCell

50

A new study from the Center for Integration of Science and Industry at Bentley University shows that differences between the financial structures of large pharmaceutical producers and smaller, emerging biotechnology companies creates synergies that contribute to the pipeline of new, innovative products in response to reductions in drug prices anticipated under the Inflation Reduction Act (IRA). The study in Clinical Trials titled “Modeling impact of Inflation Reduction Act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies” suggests that while large pharmaceutical producers would likely reduce R&D spending in response to lower product revenues, R&D in smaller biotechnology companies is not likely to decrease and could sustain both corporate profits and new product approvals at current levels. Therefore, claims that the IRA would reduce the number of new drugs for unmet medical needs are likely false. Authors: Greg Vaughan, Roger Du, CPA, Fred Ledley https://lnkd.in/eARtw54U #InflationReductionAct #innovation #drugprices #drugdevelopment #investment #BentleyUResearch Bentley University Bentley University Center for Health and Business

5

Nanomedicine: A New Era in Precision Health Nanomedicine is transforming the landscape of disease treatment through groundbreaking innovations like targeted therapies, personalized drug delivery, and wearable diagnostics. By harnessing advanced technologies such as stimuli-responsive nanoparticles and electrochemical sensors, these treatments can precisely target affected tissues, significantly reducing side effects on healthy cells. This innovative approach holds immense promise for managing conditions such as cancer, genetic disorders, and chronic diseases, offering customized treatments alongside real-time monitoring for optimal patient outcomes. As the field progresses, nanomedicine is poised to become a cornerstone of precision medicine, enhancing both treatment efficacy and patient care. Chosen by @Lena Qawasmi #PersonalizedMedicine #Nanomedicine #PrecisionMedicine #Innovations https://lnkd.in/dAQ-aa28

3

It’s called MauriceFlex for a reason. The platform enables offline and flexible characterization of fractionated charge variants. In this webinar we will show a workflow to easily get binding data of charge variants! #innovation #science #biotechne #spr

41

We are excited to share groundbreaking news from our innovative partner, AMSBIO. AMSBIO has introduced CellO-IF, an all-in-one reagent kit for immunofluorescent staining, designed to simplify the labeling of organoids and spheroids directly within hydrogels or extracellular matrices while preserving their delicate structures and cellular integrity. Immunofluorescence (IF) enables the detection and localization of antigens in a wide variety of tissue types. It offers higher sensitivity and signal amplification compared to immunohistochemistry. However, traditional IF methods involve multiple steps and are time-consuming. CellO-IF transforms this process by streamlining the workflow. With CellO-IF, there’s no need for harvesting, clearing, transferring, or centrifuging, which reduces sample loss and produces high-quality results in just a few hours. This simplified approach speeds up research while maintaining the natural 3D structure of samples, ensuring more accurate results. Offering superior antigen visualization, CellO-IF consistently delivers high-resolution images and is particularly effective for labeling samples with primary antibodies that previously failed with conventional methods. Available in two optimized formats for labeling both 3D and 2D samples, CellO-IF enhances target signal, providing clearer images and deeper insights for your research. Read more at: https://lnkd.in/gzPBgCBM Krystyna Joyce Bill Bradbury Alex Sim

5

Join us at the Drug Discovery Biology Strategy Meeting this November 12th in Boston to hear from Anitha Krishnan, Ph.D, Executive Director of Research at Aviceda Therapeutics. Anitha brings over a decade of innovative scientific expertise in biochemical, immunological, and molecular biology techniques. Her work is pivotal in gene therapy and cell transplantation studies, targeting ocular diseases such as Glaucoma and Age-related Macular Degeneration. She has made significant strides in understanding immune responses in neurodegeneration and autoimmune diseases, particularly through her research on microglial and macrophages and the Fas-FasL system. Anitha will be delving into the "Opportunities and Risks in the Preclinical Development of Molecules that Do Not Cross React with Rodents," offering invaluable insights from her extensive experience in advancing therapeutic approaches from discovery through to clinical trials. Don't miss the opportunity to gain from her comprehensive expertise and her knack for leading innovative preclinical research. #DrugDiscovery #BiomedicalResearch #OcularDiseases #PreclinicalDevelopment #BostonEvents #LifeSciences #StrategyMeetings

53

2 Comments

This week, find us at Discovery US 2024 in Boston where we'll share insights into how we are using AI and map-based drug discovery to advance new potential treatments. ▪ On Nov. 8 at 9:30am, Noel Powell, senior director of medicinal chemistry, presents “Recursion’s Phenomic Map-Based Drug Discovery Approach: From Project Ideation To Lead Optimization.” He'll discuss how the Recursion OS provides a mapping and navigating approach that enables us not only to unravel the complexity of biology but also to identify chemical starting points and drive SAR, allowing us to efficiently advance projects from initiation through different stages of pre-clinical development. ▪ On Nov. 8 at 10:20am, Julie Owen, director of chemistry, presents  “Targeting The Unknown: AI’s Shortcut To Drug Discovery.” She'll explain how we are using AI and data-driven approaches to radically improve the efficiency of drug discovery – commanding massive experimental and computational scale and uniting technology, biology and chemistry to advance the future of medicine. 👉 Learn more and register here: https://lnkd.in/eiVG3w28 #DiscoveryUS #DiscoveryUS24 #chemistry #smallmolecules #drugdiscovery #techbio #AI

44

Ten Companies to Watch in AI Drug Discovery https://lnkd.in/gCWtSdiZ In AI-based drug discovery—a field benefiting from a cumulative investment of $60 billion—the leaders are making real progress toward approved therapies. The post Ten Companies to Watch in AI Drug Discovery appeared first on GEN [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

1

Affini-T’s Ankit Gupta, Senior Director, Head of Gene Editing, will present “AFNT-212: A Non-Viral Gene-Edited TCR-T Cell Therapy” to industry and academic leaders at the 5th Genome Editing Therapeutics Summit in #Boston today. Learn more about it here: https://bit.ly/3BflF2Q. #CRISPR #GeneEditing #DrugDevelopment #TCells

60

🚨 Webinar Announcement: Improving Outcomes and Access to Precision Medicine🚨- https://lnkd.in/eSvkPZPG Despite groundbreaking advances in precision medicine, a critical gap remains: the lack of diverse representation in genomic data, leading to unequal healthcare outcomes—especially for people of color. 🔬 What is the impact? Genomic testing is a cornerstone of modern medicine, yet current databases are largely based on data from individuals of European descent. This leaves underrepresented populations at a disadvantage, with less effective treatments and limited access to life-saving innovations. 💡What you’ll learn: 1️⃣ Understanding the genomic testing gap and the structural barriers in healthcare 2️⃣ How to advance precision medicine for all, ensuring inclusivity 3️⃣ Practical strategies for improving access, including policy changes, community engagement, and innovative healthcare models 📅 Date: Thursday, 21st November, 2024 ⏰ Time: 12:00pm - 1:00pm ET 📍 Location: Zoom (Register Here https://lnkd.in/eSvkPZPG) Let’s work together to create a healthcare system that serves everyone. #PrecisionMedicine #GenomicTesting #HealthEquity

15

1 Comment

🚀 Thrilled to be part of this collaboration with NAYA Biosciences! 🚀 NAYA Biosciences (NASDAQ: NAYA) is developing a groundbreaking new PD-1 x VEGF antibody for cancer treatment, and MAbSilico is proud to be their AI partner in this exciting venture. By combining NAYA's innovative tetravalent scaffold technology with our AI-powered #antibody design expertise, we aim to create a best-in-class therapy with the potential to transform cancer care. This partnership exemplifies MAbSilico's commitment to pushing the boundaries of antibody drug discovery through AI. We're excited to see the impact this collaboration will have on patients' lives. #AIDrugDiscovery #AntibodyEngineering #ImmunoOncology #CancerTreatment #Partnerships #Innovation

58

5 Comments